Dhunseri Invest. (DHUNINV)
Asset PlayFairStock Score: 23/100 — RISKY
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹1,063.5 |
| Market Cap | ₹648.43 Cr |
| P/E Ratio | 35.71 |
| ROCE | 5.96% |
| ROE | 1.35% |
| Dividend Yield | 0.31% |
| Profit Growth | 182.64% |
| Debt/Equity | 0.27 |
| Sales Growth | 199.15% |
| Promoter Holding | 74.95% |
| 52-Week Range | ₹667.1 — ₹1,573.1 |
| Sector | Finance |
| Book Value | ₹817.61 |
Strengths
- Low leverage with debt/equity of only 0.15
- Book value of ₹817.61 provides an asset base; price is only 1.18 times book
- High promoter holding of 74.95% aligns ownership with management
- Small dividend yield of 0.31% shows some capital discipline, though minimal
Concerns
- Negative ROE of -1.17% and latest quarter net loss of ₹1 crore
- Sales growth of -44.27% and profit growth of -125.04% show severe deterioration
- Piotroski F-Score of 3/9 indicates weak financial health
- P/E of 0.00 and price above book without earnings power leave no margin of safety
AI Analysis
Let me start with what I look for in any investment: a business with a durable advantage and proven earning power. Dhunseri Invest, a non-banking finance company, shows neither today. Its P/E is 0.00 because trailing profits have vanished; profit growth is -125.04% and the latest quarter booked a net loss of ₹1 crore on sales of ₹70 crore. The sales decline of -44.27% tells me the underlying earning engine is shrinking, not growing. Return on equity is -1.17%, so the company is not generating value from the equity shareholders have entrusted to it. The balance sheet does provide some discipline: debt/equity is only 0.15 and book value is ₹817.61. At ₹968, the market price is 1.18 times book—not a deep discount, just a modest premium to assets with weak earnings. The Piotroski F-score of 3/9 reinforces my caution; it signals financial stress. Yes, promoter holding of 74.95% aligns management with shareholders, but a 0.31% dividend is hardly a reason to wait. In Graham's language, I buy assets below net worth with a margin of safety, or I buy earnings power at a reasonable price. Here I get neither. This is an asset play at best, but only if the book value is real and recoverable. I would need proof: rising return on equity, positive quarterly profits, and a halt to revenue erosion. Until then, this is not an investment for the patient value seeker.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer